MassDevice Q&A

June 30, 2009 by MassDevice staff

Q&A Features

01/20/2014 by Arezu Sarvestani

Cardiologist Dr. Darrel Francis finds himself attempting once again to drag the conversation back from the edge of hyperbole as the market reacts to the lackluster outcome of Medtronic's highly anticipated Symplicity HTN-3 trial of renal denervation in treatment of hypertension.

Managing renal denervation expectations in the aftermath of Symplicity HTN-3

Medtronic (NYSE:...

12/05/2013 by Arezu Sarvestani

Neurosurgeon Dr. Philip Starr tells about Medtronic's new Activa PC+S brain monitoring, recording and stimulating implant and its potential for treating neurological and psychiatric disease.

Medtronic, the 'brain pacemaker' and the future of neurological disease treatment

Deep-brain stimulation is about to get a major upgrade and medtech titan Medtronic (NYSE:...

11/25/2013 by Brian Johnson

ResMed CEO Mick Farrell tells about the history of ResMed, its sleep apnea devices and the future of treating chronic disease.

The story behind ResMed's (NYSE:RMD) meteoric rise from Baxter spinout to $1.5 billion medical device Goliath is no snore.

Or maybe it is. After all, stopping snoring has paid off pretty nicely for the San Diego-based sleep apnea device company, which has a more than 40% share in the growing market for...

11/20/2013 by Chris Walker

CEO Josh Kornberg tells about cleaning house and how bad news for rival Stryker Corp. is helping to reinvigorate Skyline Medical. Q&A: Skyline CEO Josh Kornberg

When John Kornberg joined then-BioDrain Medical in 2011 as an investor, the company had spent the past decade developing its Streamway surgical waste management device and getting clearance to commercialize it in the U.S. But, Kornberg told recently, it was quickly apparent that BioDrain was stalled, unable to leverage its 510(k) clearance from the FDA into significant U....

11/01/2013 by Arezu Sarvestani

Renal denervation has won a lot of praise as a potential solution for patients with resistant hypertension, but the excessive celebration of early clinical trial results may be setting everyone up for a major letdown and a harsh backlash. This week cardiologists at the Transcatheter Cardiovascular Therapeutics conference, including those involved with Medtronic's and Boston Scientific's clinical trials, warned of the dangers of exaggeration.

Deflating the hype: Are we setting renal denervation up for disappointment?

Renal denervation is still in its youth, but the limited clinical trials and lack of substantial confirmation hasn't curbed much of the hype for the technology as a means of treating patients with...

10/16/2013 by Brian Johnson

CeQur CEO Jim Peterson discusses the motivation behind his mission to improve the lives of patients who suffer from Type II diabetes.

Diabetes: CeQur CEO Jim Peterson's personal mission to improve the standard of care

Most people are brought into the medical device industry because of a passion for a specific disease or a personal connection to a condition that's had an impact on his or her life.

For Jim Peterson, the CEO and founder of CeQur, that motivation was right inside his own house. His daughter was diagnosed...

Syndicate content